U.S. markets open in 7 hours 1 minute

Seelos Therapeutics, Inc. (SEEL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.0900-0.1100 (-5.00%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close2.2000
Open2.1700
Bid0.0000 x 3000
Ask0.0000 x 2900
Day's Range2.0800 - 2.1718
52 Week Range0.5600 - 6.6000
Volume1,700,077
Avg. Volume4,373,326
Market Cap213.665M
Beta (5Y Monthly)3.09
PE Ratio (TTM)N/A
EPS (TTM)-0.6240
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • 10 Best Psychedelic Stocks to Buy Now
    Insider Monkey

    10 Best Psychedelic Stocks to Buy Now

    In this article, we discuss the 10 best psychedelic stocks to buy now. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Psychedelic Stocks to Buy Now. Psychedelic treatments for mental health disorders like depression, anxiety, and post-traumatic stress have revolutionized the industry in the past few […]

  • Seelos Therapeutics to Participate in Two Investor Conferences in August
    PR Newswire

    Seelos Therapeutics to Participate in Two Investor Conferences in August

    Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it will participate in two investor conferences: the BTIG Virtual Biotechnology Conference on August 9th and 10th and the Canaccord Growth Conference on August 11th and 12th.

  • Seelos' Single Dose Of SLS-004 Shows Reduction In Parkinson's Associated mRNA, Protein Expression
    Benzinga

    Seelos' Single Dose Of SLS-004 Shows Reduction In Parkinson's Associated mRNA, Protein Expression

    Seelos Therapeutics Inc (NASDAQ: SEEL) has announced positive in vivo data demonstrating down-regulation of SNCA mRNA and protein expression from a study of SLS-004. The SNCA gene has been implicated as a highly significant genetic risk factor for Parkinson's Disease (PD). In addition, accumulating evidence has suggested that elevated alpha-synuclein levels (α-synuclein) are causative in the pathogenesis of PD. The cohort administrated with LV vector carrying one key repressor, KRAB-MeCp2, and g